Sasaki, Mitsuhito http://orcid.org/0000-0002-3754-9027
Ueno, Hideki
Mitsunaga, Shuichi
Ohba, Akihiro
Hosoi, Hiroko
Kobayashi, Satoshi
Ueno, Makoto
Terazawa, Tetsuji
Goto, Masahiro
Inoue, Dai
Namiki, Shin
Sakamoto, Yasunari
Kondo, Shunsuke
Morizane, Chigusa
Ikeda, Masafumi
Okusaka, Takuji
Clinical trials referenced in this document:
Documents that mention this clinical trial
A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
https://doi.org/10.1007/s10147-021-02001-y
Funding for this research was provided by:
KAKENHI (JP26461039)
Article History
Received: 24 February 2021
Accepted: 25 July 2021
First Online: 8 August 2021
Declarations
:
: M. Ueno has received honoraria for speaking and research grants from Yakult Honsha and Taiho Pharmaceutical; C. Morizane has received research grants from Yakult Honsha and Taiho Pharmaceutical; M. Ikeda has received honoraria for speaking from Taiho Pharmaceutical and research grants from Yault Honsha; S. Mitsunaga has received honoraria for speaking from Pfizer Japan and research grants from Taiho Pharmaceutical; Y. Sakamoto has received research grants from Takeda Pharmaceutical; M. Sasaki, H. Ueno, A. Ohba, H. Hosoi, S. Kobayashi, T. Terazawa, M. Goto, D. Inoue, S. Namiki, S. Kondo and T. Okusaka have no conflict of interest to declare.
: This study was conducted in accordance with the principles laid down in the 1964 Declaration of Helsinki and its later amendments, and the protocol was approved by the Ethics Committee of National Cancer Center (Approval No. 2014-310) and all the institutions participating this study.
: Informed consent was obtained from all individual participants included in the study.